Thurston Group Forms Sensorium to Scale Clinical Trial Site Network

CHICAGO, IL – May 13, 2026 – Healthcare-focused private equity firm Thurston Group has officially announced its entry into the clinical research sector with the formation of Sensorium Clinical Research. The new entity is a clinical trial site network designed to consolidate and support leading research facilities across the United States, launching with an initial platform of three established sites in California and Florida.

This strategic move places Thurston Group, a firm known for scaling multi-site healthcare businesses, into the heart of the rapidly expanding and evolving world of pharmaceutical development. Sensorium will initially bring together Apex Clinical Research, Galiz Research, and Quantum Laboratories. According to the announcement, these founding partners boast a collective 75 years of experience and have successfully conducted over 400 clinical trials, establishing a strong foundation in high-demand therapeutic areas such as central nervous system disorders, respiratory conditions, and metabolic diseases.

Tapping a High-Growth, Fragmented Market

Thurston Group's venture into clinical research comes as the sector experiences unprecedented growth and transformation. The global clinical trials market is on a steep upward trajectory, projected to swell from an estimated $89 billion in 2025 to over $158 billion by 2033. This expansion is propelled by a surge in R&D investment, the increasing prevalence of chronic and complex diseases, and the dawn of personalized medicine.

However, the industry is beset by significant structural challenges. Perhaps the most persistent hurdle is patient recruitment and retention. Industry data consistently shows that approximately 80% of clinical trials fail to meet their enrollment deadlines, and up to 50% of research sites fail to enroll a single patient. This bottleneck not only causes costly delays in drug development but can also compromise the statistical power and validity of a study. Furthermore, the landscape of trial sites is highly fragmented, consisting largely of independent, smaller operations that often lack the capital, technology, and administrative support to operate at peak efficiency.

Site networks like Sensorium are emerging as a critical solution to these systemic issues. By consolidating multiple sites under a single operational umbrella, these networks can offer pharmaceutical sponsors and contract research organizations (CROs) a single point of contact, standardized procedures, broader patient access, and greater predictability. For the individual sites, joining a network provides access to capital for facility and technology upgrades, centralized administrative support for contracting and compliance, and a more stable pipeline of trial opportunities.

The Thurston Playbook Comes to Clinical Research

For Thurston Group, the formation of Sensorium is a logical extension of a well-honed investment strategy. Founded in 1986, the firm has a 40-year track record of partnering with physician-led enterprises and building them into industry-leading, multi-site platforms. With a history of returning over $4 billion in invested capital, its portfolio includes major players in dentistry, orthopedics, and medical aesthetics, such as Smile Doctors and U.S. Orthopaedic Partners.

The move into clinical research aligns perfectly with this model. "Our entrance into the clinical research space reflects Thurston's commitment to partnering with leaders across attractive, high-growth healthcare verticals," said Dan Davis, Managing Partner of Thurston Group, in the press release. "Sensorium represents a compelling opportunity to build a premier clinical trial site network by combining Thurston's operational expertise with best-in-class clinical research capabilities."

This sentiment was echoed by Dana Hayes III, a Principal at the firm, who pointed to a pivotal moment in the industry. "The clinical research industry is at an important inflection point, with sponsors and CROs increasingly prioritizing site quality, patient access, and operational reliability," Hayes stated. "Sensorium is positioned to be a differentiated partner in the space."

Building a Network on Quality and Experience

To lead this new venture, Thurston has appointed Matt Kiernan as the Chief Executive Officer of Sensorium. Kiernan is a seasoned industry veteran with over two decades of experience, including executive leadership roles at major pharmaceutical companies like Bristol Myers Squibb and Merck. Crucially, he has a proven entrepreneurial track record, having founded and led multiple clinical research organizations, including Intrinsic Clinical Systems and Pharmica Consulting, to successful private equity-backed acquisitions.

Kiernan's leadership will be vital in integrating the founding sites and executing the network's growth strategy. The initial platform's deep experience in complex therapeutic areas provides a significant competitive advantage. Their longstanding relationships with sponsors are a testament to a shared commitment to rigorous research and high-quality patient care, which Sensorium aims to amplify through its network structure.

The network model is designed to provide centralized infrastructure—handling administrative burdens like budget negotiation, contract management, and regulatory submissions—while allowing the clinical teams on the ground to focus on what they do best: conducting research and caring for patients.

A Strategy for Scalable Growth and Clinical Autonomy

Looking ahead, Sensorium, in partnership with Thurston, plans to pursue an aggressive but strategic growth plan. The primary objective is to expand the network by partnering with other high-quality clinical research sites across the United States. The focus will remain on sites with strong investigators, proven enrollment capabilities, and expertise in high-value therapeutic areas.

A key element of Thurston's strategy is a promise to preserve the core identity of its partner sites. The announcement stressed that the platform is designed to "preserve and reinforce clinical autonomy, physician leadership, and patient-centric culture." This approach is calculated to attract top-tier independent sites that may be wary of being absorbed by larger, more bureaucratic organizations that could stifle their clinical independence and unique culture.

By providing the resources to scale efficiently while honoring the clinical expertise at the site level, Sensorium aims to create a best-of-both-worlds scenario. This model offers a compelling proposition for sponsors seeking reliable, high-performing site partners and for research sites looking to grow and thrive in an increasingly complex and competitive landscape. This strategic synthesis of financial backing, operational expertise, and clinical excellence positions Sensorium to become a significant and influential force in the execution of clinical trials nationwide.